THE MEDICAL COLLEGE OF WISCONSIN, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

Recruiting

Conditions: Multiple Myeloma

Interventions: Other: Allogeneic Hematopoietic Stem Cell Transplant

First Posted Date: 2017-04-25

Last Posted Date: 2023-08-30

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 544

Registration Number: NCT03127761

Locations: 🇺🇸
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota, United States

Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Recruiting

Conditions: Myelofibrosis

Interventions: Other: Hematopoietic Stem Cell Transplant

First Posted Date: 2016-10-17

Last Posted Date: 2023-08-30

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 650

Registration Number: NCT02934477

Locations: 🇺🇸
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota, United States

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Phase 2

Completed

Conditions: Myelodysplastic Syndrome (MDS)
Chronic Lymphocytic Leukemia (CLL)
Chemotherapy-sensitive Lymphoma
Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma
Acute Myelogenous Leukemia (AML)
Acute Biphenotypic Leukemia (ABL)
Acute Undifferentiated Leukemia (AUL)

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
Drug: Cyclophosphamide 50mg/kg/day IV on Days -5,-4
Radiation: Total Body Irradiation (TBI) 200cGy on Day -1
Drug: Cyclophosphamide 50mg/kg/day IV on Days -2,-1
Drug: Busulfan
Radiation: Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1
Procedure: Infusion of non-T-cell depleted bone marrow on Day 0
Drug: Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
Drug: Sirolimus
Drug: Mycophenolate mofetil
Drug: G-CSF
Drug: Pre-HCT Mesna on Days -2 and -1
Drug: Pre-HCT Mesna on Days -5 and -4
Drug: Pre-HCT Mesna on Days -6 and -5
Drug: Post-HCT Mesna

First Posted Date: 2016-06-08

Last Posted Date: 2020-12-02

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 80

Registration Number: NCT02793544

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center - Adults, New York, New York, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Virginia Commonwealth University Massey Cancer Center Bone Marrow Transplant Program, Richmond, Virginia, United States

and more 8 locations

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia (ALL)

Interventions: Biological: Moxetumomab Pasudotox

First Posted Date: 2015-01-14

Last Posted Date: 2015-09-16

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 1

Registration Number: NCT02338050

Locations: 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 1 locations

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Active, not recruiting

Conditions: Juvenile Myelomonocytic Leukemia
Chronic Myelogenous Leukemia
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia/Lymphoma
Myelodysplasia

First Posted Date: 2015-01-14

Last Posted Date: 2023-02-08

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 340

Registration Number: NCT02338479

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸
Dana Farber Cancer Institute - Pediatrics, Boston, Massachusetts, United States

and more 29 locations

Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors

Not Applicable

Completed

Conditions: Adult Hematopoietic Cell Transplant (HCT) Survivors 1-2 Yrs Post Most Recent HCT

Interventions: Other: Individualized Survivorship Care Plan (SCP)

First Posted Date: 2014-07-25

Last Posted Date: 2017-09-07

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 495

Registration Number: NCT02200133

Locations: 🇺🇸
University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 14 locations

Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT

Phase 2

Completed

Conditions: Acute Myeloid Leukemia (AML)
Myelodysplastic Syndrome (MDS)

Interventions: Drug: Treosulfan

First Posted Date: 2013-01-21

Last Posted Date: 2016-10-12

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 40

Registration Number: NCT01772953

Locations: 🇺🇸
Washington University, St. Louis Children's, St. Louis, Missouri, United States
🇺🇸
Children's National Medical Center, Washington, DC, District of Columbia, United States
🇺🇸
Children's Hospital of Alabama/UAB, Birmingham, Alabama, United States

and more 20 locations

A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor

Phase 2

Completed

Conditions: Related Donors Donating Peripheral Blood Stem Cells (PBSC) to a Family Member
Myelodysplastic Syndrome
Hodgkin's Disease
Chronic Lymphocytic Leukemia
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Chronic Myelogenous Leukemia
Non-Hodgkin's Lymphoma

Interventions: Drug: Plerixafor

First Posted Date: 2012-10-01

Last Posted Date: 2023-09-14

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 127

Registration Number: NCT01696461

Locations: 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 9 locations

MRD Testing Before and After Hematopoietic Cell Transplantation for Pediatric Acute Myeloid Leukemia

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2011-06-30

Last Posted Date: 2017-09-07

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 150

Registration Number: NCT01385787

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
The Children's Hospital of Alabama, University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Loma Linda University, Loma Linda, California, United States

and more 35 locations

National Marrow Donor Program Long-Term Donor Follow-Up

Completed

Conditions: Hematologic Neoplasms

First Posted Date: 2011-05-30

Last Posted Date: 2020-10-20

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 21974

Registration Number: NCT01362179

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
National Marrow Donor Program Northeast District, Philadelphia, Pennsylvania, United States
🇺🇸
Baylor Research Institute, Dallas, Texas, United States

and more 26 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy